A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group (original) (raw)

Abstract

Proliferation of drug resistant tumour following chemotherapy is the principal cause of treatment failure in small cell lung cancer (SCLC). Verapamil has been shown to partially restore drug sensitivity in tumour cells rendered resistant in vitro. The results of the first large-scale randomised study of a resistance modifying drug given in conjunction with chemotherapy in cancer patients are reported. Two hundred and twenty-six patients have been entered. All patients received four cycles of cyclophosphamide (750 mg m-2), doxorubicin (40 mg m-2) and vincristine (1.4 mg m-2) on Day 1 and etoposide (75 mg m-2) on Days 1, 2 and 3, repeated at 21 day intervals. Those patients randomised to the verapamil arm received oral verapamil 120 mg qid for 5 days with each course of chemotherapy. Similar numbers of cycles of protocol treatment were given in both arms with over 75% of patients completing all four cycles. There were no significant differences in general toxicities between the two arms, except for more severe alopecia in the verapamil treatment group (P = 0.045). There was no significant difference in cardiovascular or haematological toxicity, although the median nadir white cell count after Cycle 1 chemotherapy was lower in the verapamil arm (P = 0.065) and there were significantly more dose reductions after Cycle 1 in the verapamil arm (P = 0.031). No statistically significant differences in response (P = 0.582) or survival (P = 0.290) data were seen. The absence of a significant improvement in response or survival using verapamil may relate to the low blood levels of verapamil seen in the clinic (0.8 microM), in contrast to those known to be maximally active in vitro (> 6 microM) or to the presence of other cellular mechanisms by which drug resistance develops.

813

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson A. B., 3rd, Trump D. L., Koeller J. M., Egorin M. I., Olman E. A., Witte R. S., Davis T. E., Tormey D. C. Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):795–799. [PubMed] [Google Scholar]
  2. Cole S. C., Flanagan R. J., Johnston A., Holt D. W. Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr. 1981 Nov 20;218:621–629. doi: 10.1016/s0021-9673(00)82087-7. [DOI] [PubMed] [Google Scholar]
  3. Cole S. P., Downes H. F., Slovak M. L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer. 1989 Jan;59(1):42–46. doi: 10.1038/bjc.1989.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415–424. doi: 10.1200/JCO.1989.7.4.415. [DOI] [PubMed] [Google Scholar]
  5. Ferry D. R., Glossmann H., Kaumann A. J. Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br J Pharmacol. 1985 Apr;84(4):811–824. doi: 10.1111/j.1476-5381.1985.tb17375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Figueredo A., Arnold A., Goodyear M., Findlay B., Neville A., Normandeau R., Jones A. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer. 1990 May 1;65(9):1895–1902. doi: 10.1002/1097-0142(19900501)65:9<1895::aid-cncr2820650904>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  7. Fine R. L., Koizumi S., Curt G. A., Chabner B. A. Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs. J Clin Oncol. 1987 Mar;5(3):489–495. doi: 10.1200/JCO.1987.5.3.489. [DOI] [PubMed] [Google Scholar]
  8. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  10. Kerr D. J., Graham J., Cummings J., Morrison J. G., Thompson G. G., Brodie M. J., Kaye S. B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol. 1986;18(3):239–242. doi: 10.1007/BF00273394. [DOI] [PubMed] [Google Scholar]
  11. Lai S. L., Goldstein L. J., Gottesman M. M., Pastan I., Tsai C. M., Johnson B. E., Mulshine J. L., Ihde D. C., Kayser K., Gazdar A. F. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989 Aug 2;81(15):1144–1150. doi: 10.1093/jnci/81.15.1144. [DOI] [PubMed] [Google Scholar]
  12. Merry S., Flanigan P., Schlick E., Freshney R. I., Kaye S. B. Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil. Br J Cancer. 1989 Jun;59(6):895–897. doi: 10.1038/bjc.1989.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miller R. L., Bukowski R. M., Budd G. T., Purvis J., Weick J. K., Shepard K., Midha K. K., Ganapathi R. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol. 1988 May;6(5):880–888. doi: 10.1200/JCO.1988.6.5.880. [DOI] [PubMed] [Google Scholar]
  14. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  15. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
  16. Plumb J. A., Milroy R., Kaye S. B. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol. 1990 Feb 15;39(4):787–792. doi: 10.1016/0006-2952(90)90160-m. [DOI] [PubMed] [Google Scholar]
  17. Presant C. A., Kennedy P. S., Wiseman C., Gala K., Bouzaglou A., Wyres M., Naessig V. Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study. Am J Clin Oncol. 1986 Aug;9(4):355–357. doi: 10.1097/00000421-198608000-00016. [DOI] [PubMed] [Google Scholar]
  18. Ramu A., Spanier R., Rahamimoff H., Fuks Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br J Cancer. 1984 Oct;50(4):501–507. doi: 10.1038/bjc.1984.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Souhami R. L., Bradbury I., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985 Jun;45(6):2878–2882. [PubMed] [Google Scholar]
  20. Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988 Apr 1;48(7):1926–1929. [PubMed] [Google Scholar]
  21. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735–7738. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]
  23. Yalowich J. C., Zucali J. R., Gross M., Ross W. E. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res. 1985 Oct;45(10):4921–4924. [PubMed] [Google Scholar]